Larger cohorts of RCC will need to be studied to determine whether baseline or the early increase in sPD-L1 on therapy may augment the molecular ccrcc clustering to create a clinically useful early marker for patients at greatest risk for nivolumab-refractory disease. The gene discussed is SPDL1; the disease is renal cell carcinoma.